Corbus starts registrational TEMPO-1 trial of Nectin-4 ADC sutantatug envedotin in OPSCC
The company's latest investor deck reports first dosing in the registrational study, a 43% confirmed response rate in earlier-line data, and an obesity candidate, CRB-913, with about $115M in cash.
Corbus Pharmaceuticals has updated its corporate presentation, with figures as of 30 September 2026, setting out progress across its oncology and obesity programmes. The lead oncology asset is sutantatug envedotin (SUTA-E), an antibody-drug conjugate directed at Nectin-4.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Corbus Pharmaceuticals Holdings, Inc. ↗
Article written by VigiEye from the official source (Corbus Pharmaceuticals Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.